Targeted Oncology Staff

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in multiple myeloma.

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.

During a live event, Nelson J. Chao, MD, asked participants how they employ the currently approved treatments for chronic GVHD.

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple myeloma.

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in relapsed/refractory myeloma.

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy referrals, timing, and challenges in relapsed or high-risk lymphoma.

During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and chemotherapy in patients with non–small cell lung cancer in the PD-L1–low setting.

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for teclistamab in myeloma.

During a live event, Fengting Yan, MD, PhD, discussed safety outcomes from the TROPION-Breast01 and supportive care for datopotamab deruxtecan in metastatic breast cancer.

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and axatilimab in patients with chronic graft-vs-host disease.

During a live event, Alfred L. Garfall, MD, discussed the dose adjustments and supportive care for toxicities seen with talquetamab in multiple myeloma.

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

During a live event, Heather L. McArthur, MD, MPH, reviewed genomic assays for early-stage breast cancer.

During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma and the need for monitoring for neuropathy with bortezomib.

During a live event, Priyanka Pophali, MD, MBBS, discussed CAR T-cell therapy caregiver challenges and referral considerations after DLBCL relapse.

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and compared the use of single agent vs doublet immunotherapy in the PD-L1–low setting.

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and beyond in patients with multiple myeloma.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

During a live event, Chandler H. Park, MD, and participants discuss NCCN guidelines and TiNivo-2 data for second-line renal cell carcinoma.

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia vera.

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in progressive desmoid tumors.